Beyond Air has filed a patent for a method of inhibiting the growth of tumor cells in the respiratory tract. The method involves administering gaseous nitric oxide (gNO) via inhalation at a concentration of 1 ppm to 1,000 ppm for at least 1 second per day. The gNO may be used in combination with anti-cancer therapy or an agent for treating methemoglobinemia. GlobalData’s report on Beyond Air gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Beyond Air,ambulatory infusion device was a key innovation area identified from patents. Beyond Air's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Method of inhibiting tumor growth using inhaled nitric oxide
A recently filed patent (Publication Number: US20230277582A1) describes a method for inhibiting the growth of cells or tissue in a primary and/or secondary tumor in the respiratory tract of a subject. The method involves administering gaseous nitric oxide (gNO) to the subject through inhalation for at least 1 second per day. The concentration of gNO ranges from about 1 ppm to about 1,000 ppm. The method can be effective for a time period of 1 to 100 days and can be administered from 1 to 4 times per day.
The patent also claims a method for sensitizing cells or tissue in a primary and/or secondary tumor in the respiratory tract to an anti-cancer therapy. This method involves co-administering the anti-cancer therapy and gaseous nitric oxide (gNO) through inhalation for at least 1 second per day. The concentration of gNO ranges from about 1 ppm to about 1,000 ppm. The method can be effective for a time period of 1 to 100 days and can be administered from 1 to 4 times per day.
The patent further suggests that the administration of gNO can be combined with an anti-cancer therapy such as a chemotherapeutic agent, an immune-oncological agent, or a radiation treatment. The gNO can be mixed with a carrier gas and administered for at least 10 minutes per day, but no more than about 600 minutes per day. The volumetric flow of gNO mixed with the carrier gas can range from about 1 liter per minute to about 100 liters per minute.
It is important to note that the patent also mentions the administration of an agent suitable for treating methemoglobinemia, a condition characterized by the presence of abnormal levels of methemoglobin in the blood. However, some claims in the patent have been canceled.
Overall, this patent proposes a method for inhibiting the growth of tumors in the respiratory tract and sensitizing them to anti-cancer therapies through the administration of gaseous nitric oxide. The method offers flexibility in terms of concentration, duration, and frequency of gNO administration, and can potentially be combined with other anti-cancer treatments.